Targeting tumor–stromal interactions in bone metastasis

Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) Vol. 141; no. 2; pp. 222 - 233
Main Authors: Esposito, Mark, Kang, Yibin
Format: Journal Article
Language:English
Published: Oxford Elsevier 01.02.2014
Subjects:
Animals
Biological and medical sciences
Bone Neoplasms - metabolism
Bone Neoplasms - secondary
Bone Remodeling
Diseases of the osteoarticular system
Humans
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - metabolism
Neoplasms - pathology
Stromal Cells - metabolism
Tumors
Tumors of striated muscle and skeleton
Host tumor relation
Metastatic niche
Targeting
Tumor-stromal interactions
Diseases of the osteoarticular system
Osteoclast inhibitors
Osteoclast
Immune surveillance
Malignant tumor
Tumor dormancy
Osteoarticular system
Dormancy
Immunological surveillance
Target
Bone metastasis
Advanced stage
Inhibitor
Bone
Cancer
Tumor–stromal interactions
mesenchymal stem cell
hematopoietic stem cell
T(reg)
regulatory T cell
DTC
circulating tumor cell
disseminated tumor cell
natural killer
CTC
HSC
MSC
NK
dendritic cell
DC
ISSN:0163-7258, 1879-016X, 1879-016X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone metastasis, and much of this research reveals a crucial role of the host stroma in each step of the metastatic cascade. Tumor-stromal interactions are crucial in engineering a pre-metastatic niche, accommodating metastatic seeding, and establishing the vicious cycle of bone metastasis. Current treatments in bone metastasis focus on latter steps of the metastatic cascade, with most treatments targeting the process of bone remodeling; however, emerging research identifies many other candidates as promising targets. Host stromal cells including platelets and endothelial cells are important in the early steps of metastatic homing, attachment and extravasation while a variety of immune cells, parenchymal cells and mesenchymal cells of the bone marrow are important in the establishment of overt, immune-suppressed metastatic lesions. Many participants during these steps have been identified and functionally validated. Significant contributors include integrins, (αvβ3, α2β1, α4β1), TGFβ family members, bone resident proteins (BSP, OPG, SPARC, OPN), RANKL, and PTHrP. In this review, we will discuss the contribution of host stromal cells to pre-metastatic niche conditioning, seeding, dormancy, bone-remodeling, immune regulation, and chemotherapeutic shielding in bone metastasis. Research exploring these interactions between bone metastases and stromal cells has yielded many therapeutic targets, and we will discuss both the current and future therapeutic avenues in treating bone metastasis.
AbstractList Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone metastasis, and much of this research reveals a crucial role of the host stroma in each step of the metastatic cascade. Tumor-stromal interactions are crucial in engineering a pre-metastatic niche, accommodating metastatic seeding, and establishing the vicious cycle of bone metastasis. Current treatments in bone metastasis focus on latter steps of the metastatic cascade, with most treatments targeting the process of bone remodeling; however, emerging research identifies many other candidates as promising targets. Host stromal cells including platelets and endothelial cells are important in the early steps of metastatic homing, attachment and extravasation while a variety of immune cells, parenchymal cells and mesenchymal cells of the bone marrow are important in the establishment of overt, immune-suppressed metastatic lesions. Many participants during these steps have been identified and functionally validated. Significant contributors include integrins, (αvβ3, α2β1, α4β1), TGFβ family members, bone resident proteins (BSP, OPG, SPARC, OPN), RANKL, and PTHrP. In this review, we will discuss the contribution of host stromal cells to pre-metastatic niche conditioning, seeding, dormancy, bone-remodeling, immune regulation, and chemotherapeutic shielding in bone metastasis. Research exploring these interactions between bone metastases and stromal cells has yielded many therapeutic targets, and we will discuss both the current and future therapeutic avenues in treating bone metastasis.
Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone metastasis, and much of this research reveals a crucial role of the host stroma in each step of the metastatic cascade. Tumor-stromal interactions are crucial in engineering a pre-metastatic niche, accommodating metastatic seeding, and establishing the vicious cycle of bone metastasis. Current treatments in bone metastasis focus on latter steps of the metastatic cascade, with most treatments targeting the process of bone remodeling; however, emerging research identifies many other candidates as promising targets. Host stromal cells including platelets and endothelial cells are important in the early steps of metastatic homing, attachment and extravasation while a variety of immune cells, parenchymal cells and mesenchymal cells of the bone marrow are important in the establishment of overt, immune-suppressed metastatic lesions. Many participants during these steps have been identified and functionally validated. Significant contributors include integrins, (αvβ3, α2β1, α4β1), TGFβ family members, bone resident proteins (BSP, OPG, SPARC, OPN), RANKL, and PTHrP. In this review, we will discuss the contribution of host stromal cells to pre-metastatic niche conditioning, seeding, dormancy, bone-remodeling, immune regulation, and chemotherapeutic shielding in bone metastasis. Research exploring these interactions between bone metastases and stromal cells has yielded many therapeutic targets, and we will discuss both the current and future therapeutic avenues in treating bone metastasis.Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone metastasis, and much of this research reveals a crucial role of the host stroma in each step of the metastatic cascade. Tumor-stromal interactions are crucial in engineering a pre-metastatic niche, accommodating metastatic seeding, and establishing the vicious cycle of bone metastasis. Current treatments in bone metastasis focus on latter steps of the metastatic cascade, with most treatments targeting the process of bone remodeling; however, emerging research identifies many other candidates as promising targets. Host stromal cells including platelets and endothelial cells are important in the early steps of metastatic homing, attachment and extravasation while a variety of immune cells, parenchymal cells and mesenchymal cells of the bone marrow are important in the establishment of overt, immune-suppressed metastatic lesions. Many participants during these steps have been identified and functionally validated. Significant contributors include integrins, (αvβ3, α2β1, α4β1), TGFβ family members, bone resident proteins (BSP, OPG, SPARC, OPN), RANKL, and PTHrP. In this review, we will discuss the contribution of host stromal cells to pre-metastatic niche conditioning, seeding, dormancy, bone-remodeling, immune regulation, and chemotherapeutic shielding in bone metastasis. Research exploring these interactions between bone metastases and stromal cells has yielded many therapeutic targets, and we will discuss both the current and future therapeutic avenues in treating bone metastasis.
Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have only recently been elucidated. Significant progress has been made in the past decade toward understanding the molecular underpinnings of bone metastasis, and much of this research reveals a crucial role of the host stroma in each step of the metastatic cascade. Tumor-stromal interactions are crucial in engineering a pre-metastatic niche, accommodating metastatic seeding, and establishing the vicious cycle of bone metastasis. Current treatments in bone metastasis focus on latter steps of the metastatic cascade, with most treatments targeting the process of bone remodeling; however, emerging research identifies many other candidates as promising targets. Host stromal cells including platelets and endothelial cells are important in the early steps of metastatic homing, attachment and extravasation while a variety of immune cells, parenchymal cells and mesenchymal cells of the bone marrow are important in the establishment of overt, immune-suppressed metastatic lesions. Many participants during these steps have been identified and functionally validated. Significant contributors include integrins, ( alpha v beta 3, alpha 2 beta 1, alpha 4 beta 1), TGF beta family members, bone resident proteins (BSP, OPG, SPARC, OPN), RANKL, and PTHrP. In this review, we will discuss the contribution of host stromal cells to pre-metastatic niche conditioning, seeding, dormancy, bone-remodeling, immune regulation, and chemotherapeutic shielding in bone metastasis. Research exploring these interactions between bone metastases and stromal cells has yielded many therapeutic targets, and we will discuss both the current and future therapeutic avenues in treating bone metastasis.
Author Kang, Yibin
Esposito, Mark
AuthorAffiliation 1 Department of Molecular Biology, Princeton University, Princeton, NJ. 08544
AuthorAffiliation_xml – name: 1 Department of Molecular Biology, Princeton University, Princeton, NJ. 08544
Author_xml – sequence: 1
  givenname: Mark
  surname: Esposito
  fullname: Esposito, Mark
– sequence: 2
  givenname: Yibin
  surname: Kang
  fullname: Kang, Yibin
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28319231$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/24140083$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1qGzEUhUVJaZy0r1BmU-hm3KufGWk2hRLSHwh0k0B24o4s2TIzGleSC9nlHfqGfZJqiGu3q4DgIt1PR0f3XJCzMAVLSEVhSYG2H7bL3QbjmDc24pIB5eV4CdC-IAuqZFcX5v6MLErhtWSNOicXKW0BQAhgr8g5E1QAKL4g3S3Gtc0-rKu8H6f4-_FXynEacah8yEXeZD-FVDZVXzxUo82YyvLpNXnpcEj2zaFekrvP17dXX-ub71--XX26qU0julwbLhVTXAmJzLGeWSecgQb4SjRGQtdbhgjWcaQ9iqbloqO2xcZJZw1btfySfHzS3e370a6MDTnioHfRjxgf9IRe_98JfqPX00_NO1H-LorA-4NAnH7sbcp69MnYYcBgp33StGFCUMkVfR4VHUjgQs623v5r6-jn72gL8O4AYDI4uIjB-HTiFKcd4_Ob6okzcUopWndEKOg5bb3Vp7T1nPbcKWmfRnO8anzGObAyCD88L_AHXq63xw
CODEN PHTHDT
CitedBy_id crossref_primary_10_1080_14712598_2016_1196179
crossref_primary_10_3390_cancers14194888
crossref_primary_10_3390_cells11030544
crossref_primary_10_1016_j_celrep_2024_114528
crossref_primary_10_1016_j_addr_2014_10_014
crossref_primary_10_3390_cancers14143377
crossref_primary_10_1007_s13402_016_0281_9
crossref_primary_10_1038_nrc3920
crossref_primary_10_3390_ijms17091432
crossref_primary_10_1016_j_jconrel_2018_10_008
crossref_primary_10_1063_1_4903762
crossref_primary_10_1002_path_4597
crossref_primary_10_1016_j_bonr_2022_101619
crossref_primary_10_1016_j_semcancer_2019_09_007
crossref_primary_10_1080_07357907_2016_1222416
crossref_primary_10_1016_j_jbo_2019_100227
crossref_primary_10_1007_s10585_015_9737_y
crossref_primary_10_3390_cells10112826
crossref_primary_10_1186_s12885_021_08495_z
crossref_primary_10_3389_fonc_2023_1125637
crossref_primary_10_1016_j_pharmthera_2016_03_003
crossref_primary_10_3390_ijms222011273
crossref_primary_10_3390_nu11102306
crossref_primary_10_1002_pros_23489
crossref_primary_10_1016_j_pharmthera_2019_03_007
crossref_primary_10_3390_cells10112944
crossref_primary_10_1038_ncb3015
crossref_primary_10_1158_2159_8290_CD_15_0352
crossref_primary_10_1016_j_bbamcr_2015_10_010
crossref_primary_10_1016_j_critrevonc_2021_103416
crossref_primary_10_3390_ijms22041886
crossref_primary_10_1155_2020_3462363
crossref_primary_10_1158_0008_5472_CAN_16_2129
crossref_primary_10_1002_cnr2_70044
crossref_primary_10_20517_cdr_2025_28
crossref_primary_10_1002_adfm_202100478
crossref_primary_10_1016_j_bbagen_2016_08_007
crossref_primary_10_3892_ijo_2015_2915
crossref_primary_10_1016_j_imlet_2014_03_001
crossref_primary_10_1186_s40164_024_00532_4
crossref_primary_10_1038_srep43710
crossref_primary_10_1016_j_jconrel_2014_10_012
crossref_primary_10_1371_journal_pone_0122764
crossref_primary_10_1371_journal_pone_0151731
crossref_primary_10_1016_j_semcancer_2019_08_030
crossref_primary_10_3892_ol_2018_8166
crossref_primary_10_1155_2015_434389
crossref_primary_10_1007_s12013_014_0433_3
crossref_primary_10_1369_0022155416676064
crossref_primary_10_3389_fcell_2021_639514
crossref_primary_10_1007_s10585_018_9951_5
crossref_primary_10_1016_j_canlet_2017_03_034
crossref_primary_10_1016_j_jbiomech_2020_110189
crossref_primary_10_3390_ijms17050706
crossref_primary_10_3390_ijms17081375
crossref_primary_10_1186_s13045_016_0269_y
crossref_primary_10_1111_gtc_12743
crossref_primary_10_1111_nyas_12562
crossref_primary_10_1080_14740338_2021_1861246
crossref_primary_10_1186_s12943_017_0746_0
crossref_primary_10_1371_journal_pone_0123877
crossref_primary_10_3390_ijms161225997
crossref_primary_10_1016_j_molimm_2017_11_023
crossref_primary_10_3390_ijms22094862
crossref_primary_10_1038_s41388_021_02174_w
crossref_primary_10_3389_fendo_2021_763846
crossref_primary_10_1007_s10555_017_9683_z
crossref_primary_10_1164_rccm_201503_0440SO
crossref_primary_10_3389_fphar_2015_00279
crossref_primary_10_1016_j_csbj_2022_05_051
crossref_primary_10_1007_s11914_024_00897_9
crossref_primary_10_1007_s10585_019_09997_8
crossref_primary_10_1158_1541_7786_MCR_22_0695
crossref_primary_10_1038_s43018_020_0088_5
crossref_primary_10_1007_s00109_015_1329_4
crossref_primary_10_1177_17455057221149493
crossref_primary_10_3892_ijo_2020_5045
crossref_primary_10_3389_fimmu_2024_1335366
crossref_primary_10_1146_annurev_cancerbio_041916_064715
crossref_primary_10_1016_j_clbc_2017_11_020
crossref_primary_10_3389_fonc_2021_692788
crossref_primary_10_3390_ijms21124463
crossref_primary_10_1007_s10555_023_10090_6
crossref_primary_10_5301_tj_5000423
crossref_primary_10_1002_jbmr_3618
crossref_primary_10_1016_j_nano_2020_102196
crossref_primary_10_1038_srep14284
crossref_primary_10_1016_j_bbrc_2015_10_009
crossref_primary_10_1002_cam4_6055
crossref_primary_10_1016_j_tcb_2014_12_006
crossref_primary_10_1177_107327481502200114
crossref_primary_10_1007_s00109_014_1226_2
crossref_primary_10_3389_fonc_2020_01100
crossref_primary_10_1016_j_immuni_2014_06_010
crossref_primary_10_3390_antibiotics10101202
Cites_doi 10.1016/j.ccr.2007.12.003
10.1172/JCI113411
10.1038/nrc865
10.1593/neo.12324
10.1093/jnci/djh169
10.1016/j.ccr.2011.09.009
10.1038/nrc3055
10.1083/jcb.114.3.557
10.1007/s00109-013-1021-5
10.1038/onc.2009.389
10.1158/1541-7786.MCR-08-0077
10.1158/0008-5472.CAN-06-3940
10.1002/cncr.22996
10.1158/1535-7163.MCT-11-0731
10.1172/JCI119435
10.1158/0008-5472.CAN-10-2651
10.1002/cncr.23086
10.1158/0008-5472.CAN-10-1708
10.4161/onci.1.2.18480
10.1023/B:CLIN.0000024764.93092.5f
10.1158/0008-5472.CAN-10-1254
10.1038/nature04186
10.1016/S0092-8674(00)81569-X
10.1182/blood-2004-06-2272
10.1200/JCO.2008.19.2146
10.3109/1547691X.2012.678021
10.1038/35065016
10.1158/0008-5472.CAN-11-2759
10.1182/blood-2011-04-347484
10.1084/jem.20110840
10.1172/JCI3523
10.1038/nm.2830
10.1158/0008-5472.CAN-06-4100
10.1016/j.ccr.2005.04.013
10.1186/bcr1398
10.1038/nm1351
10.1186/bcr3223
10.1038/ncb2767
10.1038/nrc2256
10.1172/JCI200317215
10.1016/j.cell.2012.10.005
10.1158/0008-5472.CAN-12-3264
10.1016/j.ccr.2010.12.022
10.1016/S0022-5347(01)65919-6
10.1093/jnci/90.2.118
10.1002/jcb.21298
10.1158/1535-7163.MCT-11-0277
10.1023/A:1025461507027
10.1111/j.1349-7006.2006.00357.x
10.1038/nature04524
10.4049/jimmunol.165.11.6015
10.1634/stemcells.2003-0196
10.1016/S0140-6736(87)92555-4
10.1158/0008-5472.CAN-06-1544
10.1016/j.bone.2010.09.016
10.1593/neo.08380
10.1023/A:1021899904332
10.1200/JCO.2009.25.0597
10.1038/ncb1794
10.1002/pros.20163
10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y
10.1073/pnas.261704098
10.1126/science.277.5322.55
10.1002/ijc.25895
10.1182/blood.V88.4.1501.bloodjournal8841501
10.1038/nm1444
10.1038/nature09262
10.1083/jcb.147.1.89
10.1158/1535-7163.MCT-05-0313
10.1016/S8756-3282(03)00086-3
10.1182/blood-2003-04-1212
10.1093/jnci/88.23.1731
10.1001/jama.1994.03510360033032
10.1002/ijc.22704
10.1016/j.ccr.2013.05.008
10.1111/j.1582-4934.2011.01285.x
10.1186/1476-4598-9-258
10.1016/S0140-6736(76)90416-5
10.1158/0008-5472.CAN-07-1286
10.4161/onci.24064
10.1073/pnas.95.16.9325
10.1007/s10585-008-9226-7
10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U
10.1002/ijc.2910510314
10.1182/blood-2003-11-3839
10.1038/nm.2753
10.1007/s10585-012-9539-4
10.1159/000054276
10.1016/j.ccr.2011.11.002
10.1038/nm0995-944
10.1158/0008-5472.CAN-11-4010
10.1016/j.bone.2006.06.004
10.1007/s10549-011-1478-2
10.1158/0008-5472.CAN-03-3958
10.1016/S0092-8674(00)80257-3
10.1111/j.1442-2042.2012.03098.x
10.1097/CJI.0b013e318247a4e7
10.1073/pnas.042372199
10.1038/nbt1281
10.1200/JCO.2003.03.091
10.1016/j.cell.2012.04.042
10.1016/S0021-9258(18)67143-1
10.1038/485S58a
10.1016/j.ccr.2013.04.017
10.1073/pnas.1432929100
10.1016/0360-3016(85)90310-4
10.1038/nm0597-558
10.1016/S1535-6108(03)00132-6
10.1158/1078-0432.728.11.2
10.1677/erc.1.00956
10.4161/onci.22338
10.1158/0008-5472.CAN-03-3853
10.1016/j.bbapap.2012.12.009
10.1023/B:CLIN.0000006873.65590.68
10.1016/S1535-6108(04)00081-9
10.1359/jbmr.2000.15.5.834
10.1158/0008-5472.CAN-05-0749
10.1158/2159-8290.CD-12-0271
10.1593/neo.06493
10.1172/JCI43414
10.1158/0008-5472.CAN-05-2814
10.1016/j.juro.2012.11.022
10.1093/jnci/djk053
10.1593/neo.111544
10.1038/nm.1943
10.1200/JCO.2000.18.1.80
10.1038/sj.bjc.6603103
10.1158/0008-5472.CAN-04-1987
10.4049/jimmunol.1101855
10.1182/blood-2008-06-162123
10.1016/j.ccr.2009.05.017
10.1002/jcp.21835
10.1074/jbc.M109.035899
10.1056/NEJMoa030847
10.1002/jcb.21220
10.1007/BF01756134
10.1002/cncr.11138
10.1158/1078-0432.CCR-10-2574
10.1101/gad.169029.111
10.1056/NEJMoa050434
10.1073/pnas.61.1.46
10.1093/jnci/87.5.348
10.1101/gad.1824809
10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q
10.1007/978-1-4615-3398-6_28
10.1038/embor.2012.41
10.1126/science.1228522
10.1016/j.cell.2004.07.004
10.1038/73193
10.1073/pnas.1331360100
10.1038/nm1519
10.1016/j.exphem.2004.11.015
10.1038/sj.bjc.6603030
10.1073/pnas.2234372100
10.1002/jcb.22131
10.1056/NEJMoa1003466
10.1016/S0090-4295(96)00182-3
10.1056/NEJM200009143431101
10.1073/pnas.1830978100
10.1126/science.1067100
10.1182/blood.V91.5.1706
10.1172/JCI42002
10.1083/jcb.153.6.1277
10.1056/NEJMoa0806285
10.1182/blood-2007-01-065995
10.1007/s11010-007-9485-7
10.1038/nrc867
10.1038/nature03703
10.1016/j.cell.2008.04.045
10.1172/JCI200422123
10.1038/nature07623
10.1056/NEJMra030831
10.1007/s10555-006-9027-x
10.1038/nature02040
10.1172/JCI11176
ContentType Journal Article
Copyright 2015 INIST-CNRS
2013.
2013 Elsevier Inc. All rights reserved 2013
Copyright_xml – notice: 2015 INIST-CNRS
– notice: 2013.
– notice: 2013 Elsevier Inc. All rights reserved 2013
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QP
5PM
DOI 10.1016/j.pharmthera.2013.10.006
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
DatabaseTitleList MEDLINE

MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1879-016X
EndPage 233
ExternalDocumentID PMC3947254
24140083
28319231
10_1016_j_pharmthera_2013_10_006
Genre Journal Article
Review
GrantInformation_xml – fundername: NIGMS NIH HHS
  grantid: T32 GM007388
– fundername: NCI NIH HHS
  grantid: R01 CA134519
– fundername: NCI NIH HHS
  grantid: R01 CA141062
GroupedDBID ---
--K
--M
.GJ
.~1
0R~
123
1B1
1RT
1~.
1~5
29O
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9DU
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
AAYXX
ABFNM
ABMAC
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFO
ACIUM
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFTJW
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CITATION
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSP
SSZ
T5K
TEORI
WUQ
Y6R
ZGI
ZXP
~G-
~HD
AACTN
BNPGV
IQODW
RIG
SSH
AGCQF
AGRNS
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QP
5PM
ID FETCH-LOGICAL-c549t-c378283847a2f2b2ef4fc0503d45c709be2aa0ef3a1ba4563491e6a5f7fec2d63
ISICitedReferencesCount 113
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000329950900009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0163-7258
1879-016X
IngestDate Tue Sep 30 15:42:15 EDT 2025
Sat Sep 27 21:42:18 EDT 2025
Sun Sep 28 10:11:08 EDT 2025
Mon Jul 21 06:02:38 EDT 2025
Wed Apr 02 07:15:17 EDT 2025
Tue Nov 18 22:03:35 EST 2025
Sat Nov 29 04:49:51 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Host tumor relation
Metastatic niche
Targeting
Tumor-stromal interactions
Diseases of the osteoarticular system
Osteoclast inhibitors
Osteoclast
Immune surveillance
Malignant tumor
Tumor dormancy
Osteoarticular system
Dormancy
Immunological surveillance
Target
Bone metastasis
Advanced stage
Inhibitor
Bone
Cancer
Tumor–stromal interactions
mesenchymal stem cell
hematopoietic stem cell
T(reg)
regulatory T cell
DTC
circulating tumor cell
disseminated tumor cell
natural killer
CTC
HSC
MSC
NK
dendritic cell
DC
Language English
License CC BY 4.0
2013.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c549t-c378283847a2f2b2ef4fc0503d45c709be2aa0ef3a1ba4563491e6a5f7fec2d63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink http://doi.org/10.1016/j.pharmthera.2013.10.006
PMID 24140083
PQID 1490703476
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3947254
proquest_miscellaneous_1524417381
proquest_miscellaneous_1490703476
pubmed_primary_24140083
pascalfrancis_primary_28319231
crossref_primary_10_1016_j_pharmthera_2013_10_006
crossref_citationtrail_10_1016_j_pharmthera_2013_10_006
PublicationCentury 2000
PublicationDate 2014-02-01
PublicationDateYYYYMMDD 2014-02-01
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Pharmacology & therapeutics (Oxford)
PublicationTitleAlternate Pharmacol Ther
PublicationYear 2014
Publisher Elsevier
Publisher_xml – name: Elsevier
References Kelly (10.1016/j.pharmthera.2013.10.006_bb0440) 2005; 65
Sawant (10.1016/j.pharmthera.2013.10.006_bb0790) 2013; 2
Liang (10.1016/j.pharmthera.2013.10.006_bb0535) 2004; 64
Khatib (10.1016/j.pharmthera.2013.10.006_bb0445) 1999; 59
Ostrand-Rosenberg (10.1016/j.pharmthera.2013.10.006_bb0705) 2000; 165
Nieswandt (10.1016/j.pharmthera.2013.10.006_bb0675) 1999; 59
Oba (10.1016/j.pharmthera.2013.10.006_bb0690) 2005; 33
Coussens (10.1016/j.pharmthera.2013.10.006_bb0185) 2002; 295
Hercbergs (10.1016/j.pharmthera.2013.10.006_bb0355) 1985; 11
Aguirre-Ghiso (10.1016/j.pharmthera.2013.10.006_bb0020) 2007; 7
Muller (10.1016/j.pharmthera.2013.10.006_bb0640) 1998; 58
Roodman (10.1016/j.pharmthera.2013.10.006_bb0755) 2004; 350
Maisonpierre (10.1016/j.pharmthera.2013.10.006_bb0595) 1997; 277
Fizazi (10.1016/j.pharmthera.2013.10.006_bb0280) 2013; 189
Labelle (10.1016/j.pharmthera.2013.10.006_bb0495) 2011; 20
Bidwell (10.1016/j.pharmthera.2013.10.006_bb0095) 2012; 18
Senger (10.1016/j.pharmthera.2013.10.006_bb0805) 1989; 9
Eyles (10.1016/j.pharmthera.2013.10.006_bb0260) 2010; 120
Dulos (10.1016/j.pharmthera.2013.10.006_bb0225) 2012; 35
Ghajar (10.1016/j.pharmthera.2013.10.006_bb0295) 2013; 15
Park (10.1016/j.pharmthera.2013.10.006_bb0725) 2007; 13
Brown (10.1016/j.pharmthera.2013.10.006_bb0130) 2006; 94
Matsuura (10.1016/j.pharmthera.2013.10.006_bb0600) 1996; 148
O'Day (10.1016/j.pharmthera.2013.10.006_bb0685) 2007; 110
Fizazi (10.1016/j.pharmthera.2013.10.006_bb0285) 2009; 27
Fiedler (10.1016/j.pharmthera.2013.10.006_bb0275) 2006; 12
Bao (10.1016/j.pharmthera.2013.10.006_bb0065) 2004; 5
Braun (10.1016/j.pharmthera.2013.10.006_bb0120) 2005; 353
Yu (10.1016/j.pharmthera.2013.10.006_bb0940) 2013; 339
Kang (10.1016/j.pharmthera.2013.10.006_bb0410) 2003; 3
Borsig (10.1016/j.pharmthera.2013.10.006_bb0105) 2002; 99
Sawant (10.1016/j.pharmthera.2013.10.006_bb0785) 2012; 189
Lamontanara (10.1016/j.pharmthera.2013.10.006_bb0510) 2013; 1834
Bandyopadhyay (10.1016/j.pharmthera.2013.10.006_bb0050) 2006; 12
Craig (10.1016/j.pharmthera.2013.10.006_bb0190) 2006; 25
Hayashi (10.1016/j.pharmthera.2013.10.006_bb0340) 2007; 101
Hüsemann (10.1016/j.pharmthera.2013.10.006_bb0375) 2008; 13
Miyake (10.1016/j.pharmthera.2013.10.006_bb0620) 1991; 114
Acharyya (10.1016/j.pharmthera.2013.10.006_bb0010) 2012; 150
Nash (10.1016/j.pharmthera.2013.10.006_bb0655) 2007; 99
Eibl (10.1016/j.pharmthera.2013.10.006_bb0240) 1996; 88
Steinman (10.1016/j.pharmthera.2013.10.006_bb0870) 2012; 14
Quesada (10.1016/j.pharmthera.2013.10.006_bb0750) 1983; 43
Yang (10.1016/j.pharmthera.2013.10.006_bb0915) 2012; 3
Gradilone (10.1016/j.pharmthera.2013.10.006_bb0320) 2011; 15
Kantoff (10.1016/j.pharmthera.2013.10.006_bb0415) 2010; 28
Lau (10.1016/j.pharmthera.2013.10.006_bb0515) 2006; 94
Lu (10.1016/j.pharmthera.2013.10.006_bb0555) 2009; 284
Sänger (10.1016/j.pharmthera.2013.10.006_bb0775) 2011; 129
Catena (10.1016/j.pharmthera.2013.10.006_bb0150) 2010; 71
Demers (10.1016/j.pharmthera.2013.10.006_bb0205) 2009; 107
Hauschka (10.1016/j.pharmthera.2013.10.006_bb0335) 1986; 261
Rosenberg (10.1016/j.pharmthera.2013.10.006_bb0765) 1994; 271
Domanska (10.1016/j.pharmthera.2013.10.006_bb0215) 2012; 14
Yin (10.1016/j.pharmthera.2013.10.006_bb0925) 1999; 103
Ehata (10.1016/j.pharmthera.2013.10.006_bb0235) 2007; 98
Zhao (10.1016/j.pharmthera.2013.10.006_bb0950) 2012; 1
Dimitroff (10.1016/j.pharmthera.2013.10.006_bb0210) 2001; 153
Cher (10.1016/j.pharmthera.2013.10.006_bb0165) 2003; 100
Carducci (10.1016/j.pharmthera.2013.10.006_bb0145) 2007; 110
Mohammad (10.1016/j.pharmthera.2013.10.006_bb0625) 2011; 71
Eghbali-Fatourechi (10.1016/j.pharmthera.2013.10.006_bb0230) 2003; 111
Lu (10.1016/j.pharmthera.2013.10.006_bb0575) 2007; 101
Jacob (10.1016/j.pharmthera.2013.10.006_bb0390) 1999; 59
Zohar (10.1016/j.pharmthera.2013.10.006_bb0955) 2000; 184
Pienta (10.1016/j.pharmthera.2013.10.006_bb0735) 1995; 87
Le Gall (10.1016/j.pharmthera.2013.10.006_bb0520) 2007; 67
Iwamura (10.1016/j.pharmthera.2013.10.006_bb0385) 1996; 48
Loberg (10.1016/j.pharmthera.2013.10.006_bb0545) 2007; 67
Ohno (10.1016/j.pharmthera.2013.10.006_bb0695) 2006; 5
Peinado (10.1016/j.pharmthera.2013.10.006_bb0730) 2012; 18
Sethi (10.1016/j.pharmthera.2013.10.006_bb0810) 2011; 19
Chu (10.1016/j.pharmthera.2013.10.006_bb0175) 2008; 6
Previdi (10.1016/j.pharmthera.2013.10.006_bb0745) 2011; 11
Lacey (10.1016/j.pharmthera.2013.10.006_bb0500) 1998; 93
Nervi (10.1016/j.pharmthera.2013.10.006_bb0670) 2009; 113
Bakewell (10.1016/j.pharmthera.2013.10.006_bb0045) 2003; 100
Ben-Eliyahu (10.1016/j.pharmthera.2013.10.006_bb0085) 2000; 8
Steeg (10.1016/j.pharmthera.2013.10.006_bb0865) 2012; 485
Barthel (10.1016/j.pharmthera.2013.10.006_bb0075) 2013; 73
Lu (10.1016/j.pharmthera.2013.10.006_bb0580) 2008; 26
Nelson (10.1016/j.pharmthera.2013.10.006_bb0660) 1995; 1
Withana (10.1016/j.pharmthera.2013.10.006_bb0910) 2012; 72
Sasaki (10.1016/j.pharmthera.2013.10.006_bb0780) 2003; 77
Kobayashi (10.1016/j.pharmthera.2013.10.006_bb0465) 2000; 60
Schneider (10.1016/j.pharmthera.2013.10.006_bb0795) 2011; 48
Shiozawa (10.1016/j.pharmthera.2013.10.006_bb0825) 2011; 121
Korpal (10.1016/j.pharmthera.2013.10.006_bb0485) 2009; 15
Ortiz (10.1016/j.pharmthera.2013.10.006_bb0700) 2003; 100
Young (10.1016/j.pharmthera.2013.10.006_bb0935) 1991; 33
Henderson (10.1016/j.pharmthera.2013.10.006_bb0350) 2006; 66
Yin (10.1016/j.pharmthera.2013.10.006_bb0920) 2003; 100
Cramer (10.1016/j.pharmthera.2013.10.006_bb0195) 1996; 156
Katayama (10.1016/j.pharmthera.2013.10.006_bb0435) 2003; 102
Schumacher (10.1016/j.pharmthera.2013.10.006_bb0800) 2013; 24
Shiao (10.1016/j.pharmthera.2013.10.006_bb0820) 2011; 25
Bagshaw (10.1016/j.pharmthera.2013.10.006_bb0040) 1992; 324
Ducy (10.1016/j.pharmthera.2013.10.006_bb0220) 1997; 89
Simeone (10.1016/j.pharmthera.2013.10.006_bb0830) 2012; 9
Childs (10.1016/j.pharmthera.2013.10.006_bb0170) 2000; 343
Mundy (10.1016/j.pharmthera.2013.10.006_bb0645) 2002; 2
Rosen (10.1016/j.pharmthera.2013.10.006_bb0760) 2001; 7
Sung (10.1016/j.pharmthera.2013.10.006_bb0875) 2011; 11
Arai (10.1016/j.pharmthera.2013.10.006_bb0035) 2004; 118
Karpatkin (10.1016/j.pharmthera.2013.10.006_bb0430) 1988; 81
Bruns (10.1016/j.pharmthera.2013.10.006_bb0135) 2012; 120
Epperly (10.1016/j.pharmthera.2013.10.006_bb0255) 2004; 18
Lehr (10.1016/j.pharmthera.2013.10.006_bb0530) 1998; 90
Goldstein (10.1016/j.pharmthera.2013.10.006_bb0310) 2010; 70
Heimburg (10.1016/j.pharmthera.2013.10.006_bb0345) 2006; 8
Kobayashi (10.1016/j.pharmthera.2013.10.006_bb0460) 2011; 208
Hodi (10.1016/j.pharmthera.2013.10.006_bb0370) 2010; 363
Koh (10.1016/j.pharmthera.2013.10.006_bb0475) 2012; 13
Paget (10.1016/j.pharmthera.2013.10.006_bb0710) 1989; 8
Smith (10.1016/j.pharmthera.2013.10.006_bb0850) 2013; 91
Baniwal (10.1016/j.pharmthera.2013.10.006_bb0055) 2010; 9
Zou (10.1016/j.pharmthera.2013.10.006_bb0960) 2004; 64
Akech (10.1016/j.pharmthera.2013.10.006_bb0030) 2010; 29
Sipkins (10.1016/j.pharmthera.2013.10.006_bb0835) 2005; 435
Yoneda (10.1016/j.pharmthera.2013.10.006_bb0930) 1997; 99
Weilbaecher (10.1016/j.pharmthera.2013.10.006_bb0905) 2011; 11
Coupland (10.1016/j.pharmthera.2013.10.006_bb0180) 2012; 72
Zhang (10.1016/j.pharmthera.2013.10.006_bb0945) 2009; 16
Banys (10.1016/j.pharmthera.2013.10.006_bb0060) 2011; 131
Lu (10.1016/j.pharmthera.2013.10.006_bb0585) 2007; 121
Koeneman (10.1016/j.pharmthera.2013.10.006_bb0470) 1999; 39
Braun (10.1016/j.pharmthera.2013.10.006_bb0115) 2000; 18
Korah (10.1016/j.pharmthera.2013.10.006_bb0480) 2004; 64
Powles (10.1016/j.pharmthera.2013.10.006_bb0740) 1976; 1
Takayama (10.1016/j.pharmthera.2013.10.006_bb0880) 2005; 25
Palumbo (10.1016/j.pharmthera.2013.10.006_bb0720) 2005; 105
Gong (10.1016/j.pharmthera.2013.10.006_bb0315) 1997; 3
Solakoglu (10.1016/j.pharmthera.2013.10.006_bb0855) 2002; 99
Sosa (10.1016/j.pharmthera.2013.10.006_bb0860) 2011; 17
Adams (10.1016/j.pharmthera.2013.10.006_bb0015) 2007; 25
Demaria (10.1016/j.pharmthera.2013.10.006_bb0200) 2005; 11
Lee (10.1016/j.pharmthera.2013.10.006_bb0525) 1996; 88
Gnant (10.1016/j.pharmthera.2013.10.006_bb0305) 2009; 360
Sisirak (10.1016/j.pharmthera.2013.10.006_bb0840) 2013; 2
Feuerer (10.1016/j.pharmthera.2013.10.006_bb0270) 2001; 92
Kamiya (10.1016/j.pharmthera.2013.10.006_bb0400) 2012; 19
van Holten-Verzantvoort (10.1016/j.pharmthera.2013.10.006_bb0895) 1987; 2
Nemeth (10.1016/j.pharmthera.2013.10.006_bb0665) 2003; 20
Glinskii (10.1016/j.pharmthera.2013.10.006_bb0300) 2012; 14
Méndez-Ferrer (10.1016/j.pharmthera.2013.10.006_bb0615) 2010; 466
Body (10.1016/j.pharmthera.2013.10.006_bb0100) 2003; 97
Chambers (10.1016/j.pharmthera.2013.10.006_bb0155) 2002; 2
Lam (10.1016/j.pharmthera.2013.10.006_bb0505) 2000; 106
Bendre (10.1016/j.pharmthera.2013.10.006_bb0090) 2003; 33
Waltregny (10.1016/j.pharmthera.2013.10.006_bb0900) 2000; 15
Fernandez Vallone (10.1016/j.pharmthera.2013.10.006_bb0265) 2013; 30
Beeton (10.1016/j.pharmthera.2013.10.006_bb0080) 2006; 39
Aguirre Ghiso (10.1016/j.pharmthera.2013.10.006_bb0025) 1999; 147
Palumbo (10.1016/j.pharmthera.2013.10.006_bb0715) 2007; 110
Imanishi (10.1016/j.pharmthera.2013.10.006_bb0380) 2007; 67
Kugler (10.1016/j.pharmthera.2013.10.006_bb0490) 2000; 6
Melchior (10.1016/j.pharmthera.2013.10.006_bb0610) 1997; 3
Hall (10.1016/j.pharmthera.2013.10.006_bb0325) 2006; 66
Kim (10.1016/j.pharmthera.2013.10.006_bb0450) 2009; 457
Karadag (10.1016/j.pharmthera.2013.10.006_bb0425) 2004; 96
Kim (10.1016/j.pharmthera.2013.10.006_bb0455) 1998; 95
Chen (10.1016/j.pharmthera.2013.10.006_bb0160) 2009; 221
Abe (10.1016/j.pharmthera.2013.10.006_bb0005) 2004; 104
Tsubaki (10.1016/j.pharmthera.2013.10.006_bb0890) 2007; 304
Brenner (10.1016/j.pharmthera.2013.10.006_bb0125) 2004; 22
Calvi (10.1016/j.pharmthera.2013.10.006_bb0140) 2003; 425
Gasic (10.1016/j.pharmthera.2013.10.006_bb0290) 1968; 61
Lu (10.1016/j.pharmthera.2013.10.006_bb0570) 2009; 23
Murray (10.1016/j.pharmthera.2013.10.006_bb0650) 2003; 20
Boucharaba (10.1016/j.pharmthera.2013.10.006_bb0110) 2004; 114
Hall (10.1016/j.pharmthera.2013.10.006_bb0330) 2008; 10
McAllister (10.1016/j.pharmthera.2013.10.006_bb0605) 2008; 133
Normanno (10.1016/j.pharmthera.2013.10.006_bb0680) 2005; 12
Kang (10.1016/j.pha
19720836 - J Biol Chem. 2009 Oct 16;284(42):29087-96
9568710 - Cell. 1998 Apr 17;93(2):165-76
14695408 - N Engl J Med. 2003 Dec 25;349(26):2483-94
17549607 - Mol Cell Biochem. 2007 Oct;304(1-2):53-60
17957189 - Nat Rev Cancer. 2007 Nov;7(11):834-46
19475568 - J Cell Physiol. 2009 Oct;221(1):98-108
15093540 - Cancer Cell. 2004 Apr;5(4):329-39
23810565 - Cancer Cell. 2013 Jul 8;24(1):130-7
23482834 - Oncoimmunology. 2013 Jan 1;2(1):e22338
18820689 - Nat Cell Biol. 2008 Nov;10(11):1349-55
10804012 - J Bone Miner Res. 2000 May;15(5):834-43
22952424 - Neoplasia. 2012 Aug;14(8):709-18
23515621 - J Mol Med (Berl). 2013 Apr;91(4):411-29
21673068 - Clin Cancer Res. 2011 Sep 15;17(18):5850-7
9689079 - Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30
12586798 - J Clin Oncol. 2003 Feb 15;21(4):624-30
8753751 - Urology. 1996 Aug;48(2):317-25
17390343 - J Cell Biochem. 2007 Jul 1;101(4):979-86
22805007 - Int J Urol. 2012 Nov;19(11):968-79
22820642 - Nat Med. 2012 Aug;18(8):1224-31
22137794 - Cancer Cell. 2011 Dec 13;20(6):701-14
17121910 - Mol Cancer Ther. 2006 Nov;5(11):2634-43
16489028 - Cancer Res. 2006 Feb 15;66(4):2250-6
10623696 - J Clin Oncol. 2000 Jan;18(1):80-6
20100959 - J Clin Oncol. 2010 Mar 1;28(7):1099-105
8120958 - JAMA. 1994 Mar 23-30;271(12):907-13
22355275 - Neoplasia. 2012 Jan;14(1):65-73
19573813 - Cancer Cell. 2009 Jul 7;16(1):67-78
10096570 - Cancer Res. 1999 Mar 15;59(6):1356-61
1283500 - Adv Exp Med Biol. 1992;324:255-68
11086031 - J Immunol. 2000 Dec 1;165(11):6015-9
18670640 - Neoplasia. 2008 Aug;10(8):797-803
22635005 - Nat Med. 2012 Jun;18(6):883-91
22266111 - Cancer Res. 2012 Mar 1;72(5):1199-209
22648501 - Nature. 2012 May 31;485(7400):S58-9
55892 - Lancet. 1976 Mar 20;1(7960):608-10
14713109 - Clin Exp Metastasis. 2003;20(8):757-66
11693896 - Cancer J. 2001 Sep-Oct;7(5):377-87
7853416 - J Natl Cancer Inst. 1995 Mar 1;87(5):348-53
22090419 - Mol Cancer Ther. 2012 Feb;11(2):350-9
17390372 - Int J Cancer. 2007 Aug 15;121(4):724-33
5246932 - Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52
10700237 - Nat Med. 2000 Mar;6(3):332-6
16862154 - Nat Med. 2006 Aug;12(8):933-8
22124112 - J Exp Med. 2011 Dec 19;208(13):2641-55
10485497 - Cancer Res. 1999 Sep 1;59(17):4453-7
11389070 - Cancer Res. 2001 Jun 1;61(11):4418-24
15894268 - Cancer Cell. 2005 May;7(5):485-96
19597504 - Nat Med. 2009 Aug;15(8):960-6
20863401 - Mol Cancer. 2010;9:258
15599396 - J Clin Invest. 2004 Dec;114(12):1714-25
12788977 - Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52
21295524 - Cancer Cell. 2011 Feb 15;19(2):192-205
8695872 - Blood. 1996 Aug 15;88(4):1501-8
22094253 - Cancer Cell. 2011 Nov 15;20(5):576-90
12548591 - Cancer. 2003 Feb 1;97(3 Suppl):887-92
3745206 - J Biol Chem. 1986 Sep 25;261(27):12665-74
14574413 - Nature. 2003 Oct 23;425(6960):841-6
9815680 - Clin Cancer Res. 1997 Feb;3(2):249-56
15548717 - Cancer Res. 2004 Nov 15;64(22):8451-5
21593787 - Nat Rev Cancer. 2011 Jun;11(6):411-25
14524530 - Clin Exp Metastasis. 2003;20(5):413-20
2686530 - Anticancer Res. 1989 Sep-Oct;9(5):1291-9
15816522 - Anticancer Res. 2005 Jan-Feb;25(1A):79-83
8683730 - J Urol. 1996 Aug;156(2 Pt 1):526-31
17371949 - Blood. 2007 Jul 1;110(1):133-41
23234632 - J Urol. 2013 Jan;189(1 Suppl):S51-7; discussion S57-8
12154349 - Nat Rev Cancer. 2002 Aug;2(8):563-72
18708358 - Mol Cancer Res. 2008 Aug;6(8):1259-67
22473297 - EMBO Rep. 2012 May;13(5):412-22
22306905 - J Immunother. 2012 Feb-Mar;35(2):169-78
23014660 - Breast Cancer Res. 2012;14(5):213
23018462 - J Immunol. 2012 Nov 1;189(9):4258-65
17216598 - J Cell Biochem. 2007 Jun 1;101(3):676-85
17886253 - Cancer. 2007 Nov 1;110(9):1959-66
20501944 - J Clin Invest. 2010 Jun;120(6):2030-9
9450571 - J Natl Cancer Inst. 1998 Jan 21;90(2):118-23
18000991 - Cancer. 2007 Dec 15;110(12):2614-27
20850578 - Bone. 2011 Jan;48(1):54-65
19122641 - Nature. 2009 Jan 1;457(7225):102-6
6336662 - Cancer Res. 1983 Feb;43(2):940-7
15378518 - Prostate. 2005 Mar 1;62(4):394-9
12602924 - Breast Cancer Res Treat. 2003 Feb;77(3):245-52
18555776 - Cell. 2008 Jun 13;133(6):994-1005
7585222 - Nat Med. 1995 Sep;1(9):944-9
15994953 - Cancer Res. 2005 Jul 1;65(13):5778-84
16462802 - Nat Med. 2006 Feb;12(2):235-9
9153295 - J Clin Invest. 1997 May 15;99(10):2509-17
1675153 - Cancer Immunol Immunother. 1991;33(3):146-52
23372014 - Science. 2013 Feb 1;339(6119):580-4
15011745 - In Vivo. 2004 Jan-Feb;18(1):1-14
2889957 - Lancet. 1987 Oct 31;2(8566):983-5
16951179 - Cancer Res. 2006 Sep 1;66(17):8648-54
12941866 - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9
19050309 - Blood. 2009 Jun 11;113(24):6206-14
11279612 - Int J Cancer. 2001 Apr 1;92(1):96-105
23277196 - Biochim Biophys Acta. 2013 Jul;1834(7):1449-59
11923519 - Science. 2002 Mar 29;295(5564):2387-92
17942921 - Cancer Res. 2007 Oct 15;67(20):9894-902
10825241 - J Cell Physiol. 2000 Jul;184(1):118-30
12750290 - Cancer Res. 2003 May 15;63(10):2631-7
17132226 - Neoplasia. 2006 Nov;8(11):939-48
11402070 - J Cell Biol. 2001 Jun 11;153(6):1277-86
16120859 - N Engl J Med. 2005 Aug 25;353(8):793-802
11120755 - J Clin Invest. 2000 Dec;106(12):1481-8
12815096 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11
14612570 - Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
9473237 - Blood. 1998 Mar 1;91(5):1706-15
19237632 - J Clin Oncol. 2009 Apr 1;27(10):1564-71
16341007 - Nature. 2005 Dec 8;438(7069):820-7
16870519 - Bone. 2006 Nov;39(5):985-90
10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300
17159986 - Nat Med. 2007 Jan;13(1):62-9
1713592 - J Cell Biol. 1991 Aug;114(3):557-65
19915614 - Oncogene. 2010 Feb 11;29(6):811-21
17312308 - J Natl Cancer Inst. 2007 Feb 21;99(4):309-21
11854515 - Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8
19479902 - J Cell Biochem. 2009 Jul 1;107(4):639-54
9204896 - Science. 1997 Jul 4;277(5322):55-60
21097719 - Cancer Res. 2011 Jan 1;71(1):164-74
11854519 - Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2246-51
12697741 - J Clin Invest. 2003 Apr;111(8):1221-30
23149920 - Cancer Res. 2013 Jan 15;73(2):942-52
15084698 - N Engl J Med. 2004 Apr 15;350(16):1655-64
15205345 - Cancer Res. 2004 Jun 15;64(12):4302-8
15199115 - J Natl Cancer Inst. 2004 Jun 16;96(12):956-65
19002595 - Clin Exp Metastasis. 2009;26(2):161-9
22770218 - Cell. 2012 Jul 6;150(1):165-78
10984562 - N Engl J Med. 2000 Sep 14;343(11):750-8
15260986 - Cell. 2004 Jul 23;118(2):149-61
22720236 - Oncoimmunology. 2012 Mar 1;1(2):152-161
19608765 - Genes Dev. 2009 Aug 15;23(16):1882-94
20703299 - Nature. 2010 Aug 12;466(7308):829-34
22836751 - Cancer Res. 2012 Sep 15;72(18):4662-71
11242036 - Nature. 2001 Mar 1;410(6824):50-6
21159629 - Cancer Res. 2010 Dec 15;70(24):10044-50
3280598 - J Clin Invest. 1988 Apr;81(4):1012-9
17237769 - Nat Biotechnol. 2007 Feb;25(2):238-43
22517906 - Blood. 2012 Sep 27;120(13):2620-30
21352474 - J Cell Mol Med. 2011 May;15(5):1066-70
17909051 - Cancer Res. 2007 Oct 1;67(19):9417-24
12154351 - Nat Rev Cancer. 2002 Aug;2(8):584-93
20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23
18167340 - Cancer Cell. 2008 Jan;13(1):58-68
23269702 - Cancer Discov. 2013 Feb;3(2):212-23
10344214 - Prostate. 1999 Jun 1;39(4):246-61
15947117 - Endocr Relat Cancer. 2005 Jun;12(2):471-82
15730850 - Exp Hematol. 2005 Mar;33(3):272-8
11389072 - Cancer Res. 2001 Jun 1;61(11):4432-6
16572175 - Nature. 2006 Mar 30;440(7084):692-6
1317363 - Int J Cancer. 1992 May 28;51(3):416-24
15959517 - Nature. 2005 Jun 16;435(7044):969-73
15579633 - Stem Cells. 2004;22(7):1128-33
9142127 - Nat Med. 1997 May;3(5):558-61
8944003 - J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7
15187021 - Blood. 2004 Oct 15;104(8):2484-91
23680145 - Cancer Cell. 2013 May 13;23(5):573-81
22027690 - Mol Cancer Ther. 2012 Jan;11(1):214-23
12763924 - Blood. 2003 Sep 15;102(6):2060-7
3980273 - Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):773-6
23762794 - Oncoimmunology. 2013 May 1;2(5):e24064
10508858 - J Cell Biol. 1999 Oct 4;147(1):89-104
23728425 - Nat Cell Biol. 2013 Jul;15(7):807-17
17160712 - Cancer Metastasis Rev. 2006 Dec;25(4):611-9
21207426 - Int J Cancer. 2011 Nov 15;129(10):2522-6
15701862 - Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
15367435 - Blood. 2005 Jan 1;105(1):178-85
9850077 - Cancer Res. 1998 Dec 1;58(23):5439-46
22524673 - J Immunotoxicol. 2012 Jul-Sep;9(3):241-7
16608535 - Breast Cancer Res. 2006;8(2):R20
16523199 - Br J Cancer. 2006 Mar 27;94(6):842-53
15231661 - Cancer Res. 2004 Jul 1;64(13):4514-22
23101634 - Cell. 2012 Oct 26;151(3):690-690.e1
17129361 - Cancer Sci. 2007 Jan;98(1):127-33
9182762 - Cell. 1997 May 30;89(5):747-54
10919677 - Cancer Res. 2000 Jul 15;60(14):3978-84
15168730 - Clin Exp Metastasis. 2004;21(2):129-38
21436587 - J Clin Invest. 2011 Apr;121(4):1298-312
23053744 - Clin Exp Metastasis. 2013 Mar;30(3):317-32
9916131 - J Clin Invest. 1999 Jan;103(2):197-206
16641914 - Br J Cancer. 2006 May 22;94(10):1496-503
19213681 - N Engl J Med. 2009 Feb 12;360(7):679-91
8546226 - Am J Pathol. 1996 Jan;148(1):55-61
21084275 - Cancer Res. 2011 Jan 1;71(1):175-84
11124582 - Neuroimmunomodulation. 2000;8(3):154-64
2673568 - Cancer Metastasis Rev. 1989 Aug;8(2):98-101
17483337 - Cancer Res. 2007 May 1;67(9):4254-63
12919697 - Bone. 2003 Jul;33(1):28-37
21455667 - Breast Cancer Res Treat. 2012 Feb;131(3):801-8
12842083 - Cancer Cell. 2003 Jun;3(6):537-49
22190457 - Genes Dev. 2011 Dec 15;25(24):2559-72
References_xml – volume: 13
  start-page: 58
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0375
  article-title: Systemic spread is an early step in breast cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.12.003
– volume: 81
  start-page: 1012
  year: 1988
  ident: 10.1016/j.pharmthera.2013.10.006_bb0430
  article-title: Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo
  publication-title: J Clin Invest
  doi: 10.1172/JCI113411
– volume: 2
  start-page: 563
  year: 2002
  ident: 10.1016/j.pharmthera.2013.10.006_bb0155
  article-title: Dissemination and growth of cancer cells in metastatic sites
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc865
– volume: 14
  start-page: 709
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0215
  article-title: CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy
  publication-title: Neoplasia
  doi: 10.1593/neo.12324
– volume: 43
  start-page: 940
  year: 1983
  ident: 10.1016/j.pharmthera.2013.10.006_bb0750
  article-title: Renal cell carcinoma: antitumor effects of leukocyte interferon
  publication-title: Cancer Res
– volume: 96
  start-page: 956
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0425
  article-title: Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djh169
– volume: 20
  start-page: 576
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0495
  article-title: Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.09.009
– volume: 11
  start-page: 411
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0905
  article-title: Cancer to bone: A fatal attraction
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3055
– volume: 114
  start-page: 557
  year: 1991
  ident: 10.1016/j.pharmthera.2013.10.006_bb0620
  article-title: A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture
  publication-title: J Cell Biol
  doi: 10.1083/jcb.114.3.557
– volume: 91
  start-page: 411
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0850
  article-title: The metastasis-promoting roles of tumor-associated immune cells
  publication-title: J Mol Med
  doi: 10.1007/s00109-013-1021-5
– volume: 29
  start-page: 811
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0030
  article-title: Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions
  publication-title: Oncogene
  doi: 10.1038/onc.2009.389
– volume: 6
  start-page: 1259
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0175
  article-title: Cadherin-11 promotes the metastasis of prostate cancer cells to bone
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-08-0077
– volume: 67
  start-page: 9894
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0520
  article-title: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3940
– volume: 110
  start-page: 1959
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0145
  article-title: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
  publication-title: Cancer
  doi: 10.1002/cncr.22996
– volume: 11
  start-page: 350
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0875
  article-title: plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0731
– volume: 99
  start-page: 2509
  year: 1997
  ident: 10.1016/j.pharmthera.2013.10.006_bb0930
  article-title: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
  publication-title: J Clin Invest
  doi: 10.1172/JCI119435
– volume: 71
  start-page: 175
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0625
  article-title: TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2651
– volume: 110
  start-page: 2614
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0685
  article-title: Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies
  publication-title: Cancer
  doi: 10.1002/cncr.23086
– volume: 71
  start-page: 164
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0150
  article-title: PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1708
– volume: 1
  start-page: 152
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0950
  article-title: Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
  publication-title: OncoImmunology
  doi: 10.4161/onci.1.2.18480
– volume: 21
  start-page: 129
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0815
  article-title: Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247
  publication-title: Clin Exp Metastasis
  doi: 10.1023/B:CLIN.0000024764.93092.5f
– volume: 70
  start-page: 10044
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0310
  article-title: Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1254
– volume: 438
  start-page: 820
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0420
  article-title: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
  publication-title: Nature
  doi: 10.1038/nature04186
– volume: 93
  start-page: 165
  year: 1998
  ident: 10.1016/j.pharmthera.2013.10.006_bb0500
  article-title: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81569-X
– volume: 105
  start-page: 178
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0720
  article-title: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
  publication-title: Blood
  doi: 10.1182/blood-2004-06-2272
– volume: 27
  start-page: 1564
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0285
  article-title: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.2146
– volume: 9
  start-page: 241
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0830
  article-title: Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1
  publication-title: J Immunotoxicol
  doi: 10.3109/1547691X.2012.678021
– volume: 410
  start-page: 50
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0635
  article-title: Involvement of chemokine receptors in breast cancer metastasis
  publication-title: Nature
  doi: 10.1038/35065016
– volume: 72
  start-page: 1199
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0910
  article-title: Cathepsin B inhibition limits bone metastasis in breast cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-2759
– volume: 120
  start-page: 2620
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0135
  article-title: Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells
  publication-title: Blood
  doi: 10.1182/blood-2011-04-347484
– volume: 208
  start-page: 2641
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0460
  article-title: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
  publication-title: J Exp Med
  doi: 10.1084/jem.20110840
– volume: 103
  start-page: 197
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0925
  article-title: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
  publication-title: J Clin Invest
  doi: 10.1172/JCI3523
– volume: 18
  start-page: 1224
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0095
  article-title: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
  publication-title: Nat Med
  doi: 10.1038/nm.2830
– volume: 67
  start-page: 4254
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0380
  article-title: Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-4100
– volume: 7
  start-page: 485
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0590
  article-title: MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.04.013
– volume: 8
  start-page: R20
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0845
  article-title: Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr1398
– volume: 12
  start-page: 235
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0275
  article-title: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation
  publication-title: Nat Med
  doi: 10.1038/nm1351
– volume: 14
  start-page: 213
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0870
  article-title: Zoledronic acid effectiveness against breast cancer metastases — A role for estrogen in the microenvironment?
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3223
– volume: 15
  start-page: 807
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0295
  article-title: The perivascular niche regulates breast tumour dormancy
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2767
– volume: 7
  start-page: 834
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0020
  article-title: Models, mechanisms and clinical evidence for cancer dormancy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2256
– volume: 111
  start-page: 1221
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0230
  article-title: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
  publication-title: J Clin Investig
  doi: 10.1172/JCI200317215
– volume: 151
  start-page: 690-690
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0245
  article-title: SnapShot: Bone metastasis
  publication-title: Cell
  doi: 10.1016/j.cell.2012.10.005
– volume: 73
  start-page: 942
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0075
  article-title: Definition of molecular determinants of prostate cancer cell bone extravasation
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-3264
– volume: 19
  start-page: 192
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0810
  article-title: Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.12.022
– volume: 156
  start-page: 526
  year: 1996
  ident: 10.1016/j.pharmthera.2013.10.006_bb0195
  article-title: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts
  publication-title: J Urol
  doi: 10.1016/S0022-5347(01)65919-6
– volume: 90
  start-page: 118
  year: 1998
  ident: 10.1016/j.pharmthera.2013.10.006_bb0530
  article-title: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/90.2.118
– volume: 101
  start-page: 979
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0340
  article-title: Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.21298
– volume: 11
  start-page: 214
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0745
  article-title: Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0277
– volume: 20
  start-page: 413
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0665
  article-title: Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases
  publication-title: Clin Exp Metastasis
  doi: 10.1023/A:1025461507027
– volume: 98
  start-page: 127
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0235
  article-title: Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2006.00357.x
– volume: 440
  start-page: 692
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0395
  article-title: Regulation of cancer cell migration and bone metastasis by RANKL
  publication-title: Nature
  doi: 10.1038/nature04524
– volume: 165
  start-page: 6015
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0705
  article-title: Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.11.6015
– volume: 61
  start-page: 4432
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0630
  article-title: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
  publication-title: Cancer Res
– volume: 22
  start-page: 1128
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0125
  article-title: CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells
  publication-title: Stem Cells
  doi: 10.1634/stemcells.2003-0196
– volume: 61
  start-page: 4418
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0360
  article-title: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases
  publication-title: Cancer Res
– volume: 2
  start-page: 983
  year: 1987
  ident: 10.1016/j.pharmthera.2013.10.006_bb0895
  article-title: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment
  publication-title: Lancet
  doi: 10.1016/S0140-6736(87)92555-4
– volume: 66
  start-page: 8648
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0325
  article-title: Type I collagen receptor (2 1) signaling promotes the growth of human prostate cancer cells within the bone
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1544
– volume: 48
  start-page: 54
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0795
  article-title: Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions
  publication-title: Bone
  doi: 10.1016/j.bone.2010.09.016
– volume: 59
  start-page: 4453
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0390
  article-title: Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone
  publication-title: Cancer Res
– volume: 10
  start-page: 797
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0330
  article-title: Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase
  publication-title: Neoplasia
  doi: 10.1593/neo.08380
– volume: 77
  start-page: 245
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0780
  article-title: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer
  publication-title: Breast Cancer Res Treat
  doi: 10.1023/A:1021899904332
– volume: 28
  start-page: 1099
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0415
  article-title: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.0597
– volume: 10
  start-page: 1349
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0365
  article-title: The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1794
– volume: 62
  start-page: 394
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0540
  article-title: Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.20163
– volume: 184
  start-page: 118
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0955
  article-title: Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration
  publication-title: J Cell Physiol
  doi: 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y
– volume: 99
  start-page: 2193
  year: 2002
  ident: 10.1016/j.pharmthera.2013.10.006_bb0105
  article-title: Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.261704098
– volume: 277
  start-page: 55
  year: 1997
  ident: 10.1016/j.pharmthera.2013.10.006_bb0595
  article-title: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
  publication-title: Science
  doi: 10.1126/science.277.5322.55
– volume: 59
  start-page: 1295
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0675
  article-title: Lysis of tumor cells by natural killer cells in mice is impeded by platelets
  publication-title: Cancer Res
– volume: 129
  start-page: 2522
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0775
  article-title: Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25895
– volume: 58
  start-page: 5439
  year: 1998
  ident: 10.1016/j.pharmthera.2013.10.006_bb0640
  article-title: EblacZ tumor dormancy in bone marrow and lymph nodes: Active control of proliferating tumor cells by CD8+ immune T cells
  publication-title: Cancer Res
– volume: 88
  start-page: 1501
  year: 1996
  ident: 10.1016/j.pharmthera.2013.10.006_bb0240
  article-title: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
  publication-title: Blood
  doi: 10.1182/blood.V88.4.1501.bloodjournal8841501
– volume: 12
  start-page: 933
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0050
  article-title: Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression
  publication-title: Nat Med
  doi: 10.1038/nm1444
– volume: 466
  start-page: 829
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0615
  article-title: Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
  publication-title: Nature
  doi: 10.1038/nature09262
– volume: 147
  start-page: 89
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0025
  article-title: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
  publication-title: J Cell Biol
  doi: 10.1083/jcb.147.1.89
– volume: 5
  start-page: 2634
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0695
  article-title: A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-05-0313
– volume: 33
  start-page: 28
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0090
  article-title: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease
  publication-title: Bone
  doi: 10.1016/S8756-3282(03)00086-3
– volume: 25
  start-page: 79
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0880
  article-title: The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression
  publication-title: Anticancer Res
– volume: 102
  start-page: 2060
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0435
  article-title: PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: Evidence for cooperation between E-selectin ligands and alpha4 integrin
  publication-title: Blood
  doi: 10.1182/blood-2003-04-1212
– volume: 88
  start-page: 1731
  year: 1996
  ident: 10.1016/j.pharmthera.2013.10.006_bb0525
  article-title: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/88.23.1731
– volume: 271
  start-page: 907
  year: 1994
  ident: 10.1016/j.pharmthera.2013.10.006_bb0765
  article-title: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
  publication-title: JAMA
  doi: 10.1001/jama.1994.03510360033032
– volume: 121
  start-page: 724
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0585
  article-title: PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22704
– volume: 24
  start-page: 130
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0800
  article-title: Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.05.008
– volume: 15
  start-page: 1066
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0320
  article-title: Circulating tumour cells lacking cytokeratin in breast cancer: The importance of being mesenchymal
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2011.01285.x
– volume: 60
  start-page: 3978
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0465
  article-title: Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression
  publication-title: Cancer Res
– volume: 9
  start-page: 258
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0055
  article-title: Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-9-258
– volume: 1
  start-page: 608
  year: 1976
  ident: 10.1016/j.pharmthera.2013.10.006_bb0740
  article-title: Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin
  publication-title: Lancet
  doi: 10.1016/S0140-6736(76)90416-5
– volume: 67
  start-page: 9417
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0545
  article-title: Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-1286
– volume: 2
  start-page: e24064
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0790
  article-title: Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
  publication-title: OncoImmunology
  doi: 10.4161/onci.24064
– volume: 95
  start-page: 9325
  year: 1998
  ident: 10.1016/j.pharmthera.2013.10.006_bb0455
  article-title: P-selectin deficiency attenuates tumor growth and metastasis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.95.16.9325
– volume: 26
  start-page: 161
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0580
  article-title: Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-008-9226-7
– volume: 39
  start-page: 246
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0470
  article-title: Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
  publication-title: Prostate
  doi: 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U
– volume: 51
  start-page: 416
  year: 1992
  ident: 10.1016/j.pharmthera.2013.10.006_bb0250
  article-title: Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: Effect of estrogen and progesterone
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910510314
– volume: 104
  start-page: 2484
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0005
  article-title: Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: A vicious cycle between bone destruction and myeloma expansion
  publication-title: Blood
  doi: 10.1182/blood-2003-11-3839
– volume: 18
  start-page: 883
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0730
  article-title: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
  publication-title: Nat Med
  doi: 10.1038/nm.2753
– volume: 30
  start-page: 317
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0265
  article-title: Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-012-9539-4
– volume: 8
  start-page: 154
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0085
  article-title: Suppression of NK cell activity and of resistance to metastasis by stress: A role for adrenal catecholamines and beta-adrenoceptors
  publication-title: Neuroimmunomodulation
  doi: 10.1159/000054276
– volume: 20
  start-page: 701
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0565
  article-title: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.11.002
– volume: 1
  start-page: 944
  year: 1995
  ident: 10.1016/j.pharmthera.2013.10.006_bb0660
  article-title: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
  publication-title: Nat Med
  doi: 10.1038/nm0995-944
– volume: 72
  start-page: 4662
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0180
  article-title: Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-4010
– volume: 39
  start-page: 985
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0080
  article-title: Osteoclast formation and bone resorption are inhibited by megakaryocytes
  publication-title: Bone
  doi: 10.1016/j.bone.2006.06.004
– volume: 131
  start-page: 801
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0060
  article-title: Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-011-1478-2
– volume: 64
  start-page: 4302
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0535
  article-title: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-03-3958
– volume: 89
  start-page: 747
  year: 1997
  ident: 10.1016/j.pharmthera.2013.10.006_bb0220
  article-title: Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80257-3
– volume: 19
  start-page: 968
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0400
  article-title: Clinical usefulness of bone markers in prostate cancer with bone metastasis
  publication-title: Int J Urol
  doi: 10.1111/j.1442-2042.2012.03098.x
– volume: 35
  start-page: 169
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0225
  article-title: PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer
  publication-title: J Immunother
  doi: 10.1097/CJI.0b013e318247a4e7
– volume: 99
  start-page: 2246
  year: 2002
  ident: 10.1016/j.pharmthera.2013.10.006_bb0855
  article-title: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.042372199
– volume: 7
  start-page: 377
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0760
  article-title: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial
  publication-title: Cancer J
– volume: 25
  start-page: 238
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0015
  article-title: Therapeutic targeting of a stem cell niche
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1281
– volume: 21
  start-page: 624
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0770
  article-title: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.03.091
– volume: 150
  start-page: 165
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0010
  article-title: A CXCL1 paracrine network links cancer chemoresistance and metastasis
  publication-title: Cell
  doi: 10.1016/j.cell.2012.04.042
– volume: 261
  start-page: 12665
  year: 1986
  ident: 10.1016/j.pharmthera.2013.10.006_bb0335
  article-title: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)67143-1
– volume: 485
  start-page: S58
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0865
  article-title: Perspective: The right trials
  publication-title: Nature
  doi: 10.1038/485S58a
– volume: 23
  start-page: 573
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0405
  article-title: Tumor cell dissemination: Emerging biological insights from animal models and cancer patients
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.04.017
– volume: 59
  start-page: 1356
  year: 1999
  ident: 10.1016/j.pharmthera.2013.10.006_bb0445
  article-title: Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells
  publication-title: Cancer Res
– volume: 100
  start-page: 8407
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0700
  article-title: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1432929100
– volume: 11
  start-page: 773
  year: 1985
  ident: 10.1016/j.pharmthera.2013.10.006_bb0355
  article-title: Reduced thoracic vertebrae metastases following post mastectomy parasternal irradiation
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(85)90310-4
– volume: 3
  start-page: 558
  year: 1997
  ident: 10.1016/j.pharmthera.2013.10.006_bb0315
  article-title: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
  publication-title: Nat Med
  doi: 10.1038/nm0597-558
– volume: 3
  start-page: 537
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0410
  article-title: A multigenic program mediating breast cancer metastasis to bone
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(03)00132-6
– volume: 11
  start-page: 728
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0200
  article-title: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.728.11.2
– volume: 12
  start-page: 471
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0680
  article-title: Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis
  publication-title: Endocr Relat Cancer
  doi: 10.1677/erc.1.00956
– volume: 2
  start-page: e22338
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0840
  article-title: Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients
  publication-title: OncoImmunology
  doi: 10.4161/onci.22338
– volume: 64
  start-page: 4514
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0480
  article-title: Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: An in vitro paradigm for breast cancer dormancy in bone marrow
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-03-3853
– volume: 1834
  start-page: 1449
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0510
  article-title: Mechanisms of resistance to BCR-ABL and other kinase inhibitors
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbapap.2012.12.009
– volume: 20
  start-page: 757
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0650
  article-title: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
  publication-title: Clin Exp Metastasis
  doi: 10.1023/B:CLIN.0000006873.65590.68
– volume: 5
  start-page: 329
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0065
  article-title: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(04)00081-9
– volume: 8
  start-page: 98
  year: 1989
  ident: 10.1016/j.pharmthera.2013.10.006_bb0710
  article-title: The distribution of secondary growths in cancer of the breast. 1889
  publication-title: Cancer Metastasis Rev
– volume: 15
  start-page: 834
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0900
  article-title: Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.2000.15.5.834
– volume: 65
  start-page: 5778
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0440
  article-title: Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-0749
– volume: 3
  start-page: 212
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0915
  article-title: Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0271
– volume: 8
  start-page: 939
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0345
  article-title: Inhibition of spontaneous breast cancer metastasis by anti-Thomsen–Friedenreich antigen monoclonal antibody JAA-F11
  publication-title: Neoplasia
  doi: 10.1593/neo.06493
– volume: 121
  start-page: 1298
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0825
  article-title: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow
  publication-title: J Clin Invest
  doi: 10.1172/JCI43414
– volume: 66
  start-page: 2250
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0350
  article-title: Parathyroid hormone-related protein localization in breast cancers predict improved prognosis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2814
– volume: 189
  start-page: S51
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0280
  article-title: Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.11.022
– volume: 18
  start-page: 1
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0255
  article-title: Correlation of ionizing irradiation-induced late pulmonary fibrosis with long-term bone marrow culture fibroblast progenitor cell biology in mice homozygous deletion recombinant negative for endothelial cell adhesion molecules
  publication-title: In Vivo
– volume: 99
  start-page: 309
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0655
  article-title: Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djk053
– volume: 14
  start-page: 65
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0300
  article-title: Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine
  publication-title: Neoplasia
  doi: 10.1593/neo.111544
– volume: 15
  start-page: 960
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0485
  article-title: Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis
  publication-title: Nat Med
  doi: 10.1038/nm.1943
– volume: 18
  start-page: 80
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0115
  article-title: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.1.80
– volume: 94
  start-page: 1496
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0515
  article-title: Malignant melanoma and bone resorption
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603103
– volume: 64
  start-page: 8451
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0960
  article-title: Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-1987
– volume: 189
  start-page: 4258
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0785
  article-title: Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1101855
– volume: 113
  start-page: 6206
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0670
  article-title: Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
  publication-title: Blood
  doi: 10.1182/blood-2008-06-162123
– volume: 16
  start-page: 67
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0945
  article-title: Latent bone metastasis in breast cancer tied to Src-dependent survival signals
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.05.017
– volume: 221
  start-page: 98
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0160
  article-title: Osteopontin increases migration and MMP-9 up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.21835
– volume: 284
  start-page: 29087
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0555
  article-title: Chemokine (C–C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.035899
– volume: 349
  start-page: 2483
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0885
  article-title: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa030847
– volume: 101
  start-page: 676
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0575
  article-title: CCR2 expression correlates with prostate cancer progression
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.21220
– volume: 33
  start-page: 146
  year: 1991
  ident: 10.1016/j.pharmthera.2013.10.006_bb0935
  article-title: Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/BF01756134
– volume: 9
  start-page: 1291
  year: 1989
  ident: 10.1016/j.pharmthera.2013.10.006_bb0805
  article-title: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation
  publication-title: Anticancer Res
– volume: 97
  start-page: 887
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0100
  article-title: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
  publication-title: Cancer
  doi: 10.1002/cncr.11138
– volume: 17
  start-page: 5850
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0860
  article-title: ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: Opportunities to control dormant residual disease
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2574
– volume: 25
  start-page: 2559
  year: 2011
  ident: 10.1016/j.pharmthera.2013.10.006_bb0820
  article-title: Immune microenvironments in solid tumors: New targets for therapy
  publication-title: Genes Dev
  doi: 10.1101/gad.169029.111
– volume: 353
  start-page: 793
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0120
  article-title: A pooled analysis of bone marrow micrometastasis in breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050434
– volume: 61
  start-page: 46
  year: 1968
  ident: 10.1016/j.pharmthera.2013.10.006_bb0290
  article-title: Antimetastatic effects associated with platelet reduction
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.61.1.46
– volume: 87
  start-page: 348
  year: 1995
  ident: 10.1016/j.pharmthera.2013.10.006_bb0735
  article-title: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/87.5.348
– volume: 23
  start-page: 1882
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0570
  article-title: ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis
  publication-title: Genes Dev
  doi: 10.1101/gad.1824809
– volume: 92
  start-page: 96
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0270
  article-title: Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients
  publication-title: Int J Cancer
  doi: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q
– volume: 324
  start-page: 255
  year: 1992
  ident: 10.1016/j.pharmthera.2013.10.006_bb0040
  article-title: Radiation treatment of prostate bone metastases and the biological considerations
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-3398-6_28
– volume: 13
  start-page: 412
  year: 2012
  ident: 10.1016/j.pharmthera.2013.10.006_bb0475
  article-title: The pro-metastatic role of bone marrow-derived cells: A focus on MSCs and regulatory T cells
  publication-title: EMBO Rep
  doi: 10.1038/embor.2012.41
– volume: 339
  start-page: 580
  year: 2013
  ident: 10.1016/j.pharmthera.2013.10.006_bb0940
  article-title: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
  publication-title: Science
  doi: 10.1126/science.1228522
– volume: 118
  start-page: 149
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0035
  article-title: Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche
  publication-title: Cell
  doi: 10.1016/j.cell.2004.07.004
– volume: 6
  start-page: 332
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0490
  article-title: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
  publication-title: Nat Med
  doi: 10.1038/73193
– volume: 100
  start-page: 7847
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0165
  article-title: Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1331360100
– volume: 13
  start-page: 62
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0725
  article-title: NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF
  publication-title: Nat Med
  doi: 10.1038/nm1519
– volume: 33
  start-page: 272
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0690
  article-title: MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2004.11.015
– volume: 94
  start-page: 842
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0130
  article-title: Promotion of prostatic metastatic migration towards human bone marrow stoma by omega−6 and its inhibition by omega−3 PUFAs
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603030
– volume: 100
  start-page: 14205
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0045
  article-title: Platelet and osteoclast beta3 integrins are critical for bone metastasis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2234372100
– volume: 107
  start-page: 639
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0205
  article-title: Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.22131
– volume: 363
  start-page: 711
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0370
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003466
– volume: 148
  start-page: 55
  year: 1996
  ident: 10.1016/j.pharmthera.2013.10.006_bb0600
  article-title: Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells
  publication-title: Am J Pathol
– volume: 48
  start-page: 317
  year: 1996
  ident: 10.1016/j.pharmthera.2013.10.006_bb0385
  article-title: Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen
  publication-title: Urology
  doi: 10.1016/S0090-4295(96)00182-3
– volume: 343
  start-page: 750
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0170
  article-title: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200009143431101
– volume: 100
  start-page: 10954
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0920
  article-title: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1830978100
– volume: 295
  start-page: 2387
  year: 2002
  ident: 10.1016/j.pharmthera.2013.10.006_bb0185
  article-title: Matrix metalloproteinase inhibitors and cancer — Trials and tribulations
  publication-title: Science
  doi: 10.1126/science.1067100
– volume: 91
  start-page: 1706
  year: 1998
  ident: 10.1016/j.pharmthera.2013.10.006_bb0550
  article-title: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
  publication-title: Blood
  doi: 10.1182/blood.V91.5.1706
– volume: 120
  start-page: 2030
  year: 2010
  ident: 10.1016/j.pharmthera.2013.10.006_bb0260
  article-title: Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
  publication-title: J Clin Invest
  doi: 10.1172/JCI42002
– volume: 153
  start-page: 1277
  year: 2001
  ident: 10.1016/j.pharmthera.2013.10.006_bb0210
  article-title: CD44 is a major E-selectin ligand on human hematopoietic progenitor cells
  publication-title: J Cell Biol
  doi: 10.1083/jcb.153.6.1277
– volume: 360
  start-page: 679
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0305
  article-title: Endocrine therapy plus zoledronic acid in premenopausal breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0806285
– volume: 110
  start-page: 133
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0715
  article-title: Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms
  publication-title: Blood
  doi: 10.1182/blood-2007-01-065995
– volume: 63
  start-page: 2631
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0070
  article-title: Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells
  publication-title: Cancer Res
– volume: 304
  start-page: 53
  year: 2007
  ident: 10.1016/j.pharmthera.2013.10.006_bb0890
  article-title: Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-007-9485-7
– volume: 2
  start-page: 584
  year: 2002
  ident: 10.1016/j.pharmthera.2013.10.006_bb0645
  article-title: Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc867
– volume: 435
  start-page: 969
  year: 2005
  ident: 10.1016/j.pharmthera.2013.10.006_bb0835
  article-title: In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment
  publication-title: Nature
  doi: 10.1038/nature03703
– volume: 133
  start-page: 994
  year: 2008
  ident: 10.1016/j.pharmthera.2013.10.006_bb0605
  article-title: Systemic endocrine instigation of indolent tumor growth requires osteopontin
  publication-title: Cell
  doi: 10.1016/j.cell.2008.04.045
– volume: 3
  start-page: 249
  year: 1997
  ident: 10.1016/j.pharmthera.2013.10.006_bb0610
  article-title: Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate
  publication-title: Clin Cancer Res
– volume: 114
  start-page: 1714
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0110
  article-title: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer
  publication-title: J Clin Invest
  doi: 10.1172/JCI200422123
– volume: 457
  start-page: 102
  year: 2009
  ident: 10.1016/j.pharmthera.2013.10.006_bb0450
  article-title: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
  publication-title: Nature
  doi: 10.1038/nature07623
– volume: 350
  start-page: 1655
  year: 2004
  ident: 10.1016/j.pharmthera.2013.10.006_bb0755
  article-title: Mechanisms of bone metastasis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra030831
– volume: 25
  start-page: 611
  year: 2006
  ident: 10.1016/j.pharmthera.2013.10.006_bb0190
  article-title: CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-006-9027-x
– volume: 425
  start-page: 841
  year: 2003
  ident: 10.1016/j.pharmthera.2013.10.006_bb0140
  article-title: Osteoblastic cells regulate the haematopoietic stem cell niche
  publication-title: Nature
  doi: 10.1038/nature02040
– volume: 106
  start-page: 1481
  year: 2000
  ident: 10.1016/j.pharmthera.2013.10.006_bb0505
  article-title: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand
  publication-title: J Clin Invest
  doi: 10.1172/JCI11176
– reference: 22720236 - Oncoimmunology. 2012 Mar 1;1(2):152-161
– reference: 15231661 - Cancer Res. 2004 Jul 1;64(13):4514-22
– reference: 17390343 - J Cell Biochem. 2007 Jul 1;101(4):979-86
– reference: 10919677 - Cancer Res. 2000 Jul 15;60(14):3978-84
– reference: 11086031 - J Immunol. 2000 Dec 1;165(11):6015-9
– reference: 12586798 - J Clin Oncol. 2003 Feb 15;21(4):624-30
– reference: 17237769 - Nat Biotechnol. 2007 Feb;25(2):238-43
– reference: 9916131 - J Clin Invest. 1999 Jan;103(2):197-206
– reference: 10984562 - N Engl J Med. 2000 Sep 14;343(11):750-8
– reference: 17160712 - Cancer Metastasis Rev. 2006 Dec;25(4):611-9
– reference: 15947117 - Endocr Relat Cancer. 2005 Jun;12(2):471-82
– reference: 7853416 - J Natl Cancer Inst. 1995 Mar 1;87(5):348-53
– reference: 1675153 - Cancer Immunol Immunother. 1991;33(3):146-52
– reference: 11693896 - Cancer J. 2001 Sep-Oct;7(5):377-87
– reference: 15994953 - Cancer Res. 2005 Jul 1;65(13):5778-84
– reference: 9689079 - Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30
– reference: 16641914 - Br J Cancer. 2006 May 22;94(10):1496-503
– reference: 15701862 - Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
– reference: 15959517 - Nature. 2005 Jun 16;435(7044):969-73
– reference: 19573813 - Cancer Cell. 2009 Jul 7;16(1):67-78
– reference: 15260986 - Cell. 2004 Jul 23;118(2):149-61
– reference: 16489028 - Cancer Res. 2006 Feb 15;66(4):2250-6
– reference: 10508858 - J Cell Biol. 1999 Oct 4;147(1):89-104
– reference: 11389072 - Cancer Res. 2001 Jun 1;61(11):4432-6
– reference: 23762794 - Oncoimmunology. 2013 May 1;2(5):e24064
– reference: 23372014 - Science. 2013 Feb 1;339(6119):580-4
– reference: 16608535 - Breast Cancer Res. 2006;8(2):R20
– reference: 6336662 - Cancer Res. 1983 Feb;43(2):940-7
– reference: 9568710 - Cell. 1998 Apr 17;93(2):165-76
– reference: 15548717 - Cancer Res. 2004 Nov 15;64(22):8451-5
– reference: 8695872 - Blood. 1996 Aug 15;88(4):1501-8
– reference: 23234632 - J Urol. 2013 Jan;189(1 Suppl):S51-7; discussion S57-8
– reference: 23053744 - Clin Exp Metastasis. 2013 Mar;30(3):317-32
– reference: 3980273 - Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):773-6
– reference: 18000991 - Cancer. 2007 Dec 15;110(12):2614-27
– reference: 22770218 - Cell. 2012 Jul 6;150(1):165-78
– reference: 11854519 - Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2246-51
– reference: 22306905 - J Immunother. 2012 Feb-Mar;35(2):169-78
– reference: 22090419 - Mol Cancer Ther. 2012 Feb;11(2):350-9
– reference: 23014660 - Breast Cancer Res. 2012;14(5):213
– reference: 21097719 - Cancer Res. 2011 Jan 1;71(1):164-74
– reference: 22027690 - Mol Cancer Ther. 2012 Jan;11(1):214-23
– reference: 10804012 - J Bone Miner Res. 2000 May;15(5):834-43
– reference: 21295524 - Cancer Cell. 2011 Feb 15;19(2):192-205
– reference: 17957189 - Nat Rev Cancer. 2007 Nov;7(11):834-46
– reference: 22190457 - Genes Dev. 2011 Dec 15;25(24):2559-72
– reference: 21673068 - Clin Cancer Res. 2011 Sep 15;17(18):5850-7
– reference: 19002595 - Clin Exp Metastasis. 2009;26(2):161-9
– reference: 17216598 - J Cell Biochem. 2007 Jun 1;101(3):676-85
– reference: 12815096 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11
– reference: 8683730 - J Urol. 1996 Aug;156(2 Pt 1):526-31
– reference: 12750290 - Cancer Res. 2003 May 15;63(10):2631-7
– reference: 2889957 - Lancet. 1987 Oct 31;2(8566):983-5
– reference: 16870519 - Bone. 2006 Nov;39(5):985-90
– reference: 14713109 - Clin Exp Metastasis. 2003;20(8):757-66
– reference: 10623696 - J Clin Oncol. 2000 Jan;18(1):80-6
– reference: 17549607 - Mol Cell Biochem. 2007 Oct;304(1-2):53-60
– reference: 17121910 - Mol Cancer Ther. 2006 Nov;5(11):2634-43
– reference: 18670640 - Neoplasia. 2008 Aug;10(8):797-803
– reference: 19720836 - J Biol Chem. 2009 Oct 16;284(42):29087-96
– reference: 19122641 - Nature. 2009 Jan 1;457(7225):102-6
– reference: 11279612 - Int J Cancer. 2001 Apr 1;92(1):96-105
– reference: 9450571 - J Natl Cancer Inst. 1998 Jan 21;90(2):118-23
– reference: 22517906 - Blood. 2012 Sep 27;120(13):2620-30
– reference: 10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300
– reference: 23269702 - Cancer Discov. 2013 Feb;3(2):212-23
– reference: 5246932 - Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52
– reference: 12697741 - J Clin Invest. 2003 Apr;111(8):1221-30
– reference: 21593787 - Nat Rev Cancer. 2011 Jun;11(6):411-25
– reference: 16951179 - Cancer Res. 2006 Sep 1;66(17):8648-54
– reference: 19050309 - Blood. 2009 Jun 11;113(24):6206-14
– reference: 55892 - Lancet. 1976 Mar 20;1(7960):608-10
– reference: 22137794 - Cancer Cell. 2011 Dec 13;20(6):701-14
– reference: 18708358 - Mol Cancer Res. 2008 Aug;6(8):1259-67
– reference: 21084275 - Cancer Res. 2011 Jan 1;71(1):175-84
– reference: 18167340 - Cancer Cell. 2008 Jan;13(1):58-68
– reference: 15205345 - Cancer Res. 2004 Jun 15;64(12):4302-8
– reference: 18555776 - Cell. 2008 Jun 13;133(6):994-1005
– reference: 14574413 - Nature. 2003 Oct 23;425(6960):841-6
– reference: 12548591 - Cancer. 2003 Feb 1;97(3 Suppl):887-92
– reference: 21436587 - J Clin Invest. 2011 Apr;121(4):1298-312
– reference: 22094253 - Cancer Cell. 2011 Nov 15;20(5):576-90
– reference: 21455667 - Breast Cancer Res Treat. 2012 Feb;131(3):801-8
– reference: 22473297 - EMBO Rep. 2012 May;13(5):412-22
– reference: 17886253 - Cancer. 2007 Nov 1;110(9):1959-66
– reference: 17390372 - Int J Cancer. 2007 Aug 15;121(4):724-33
– reference: 10825241 - J Cell Physiol. 2000 Jul;184(1):118-30
– reference: 23101634 - Cell. 2012 Oct 26;151(3):690-690.e1
– reference: 15579633 - Stem Cells. 2004;22(7):1128-33
– reference: 21352474 - J Cell Mol Med. 2011 May;15(5):1066-70
– reference: 12941866 - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9
– reference: 23149920 - Cancer Res. 2013 Jan 15;73(2):942-52
– reference: 19479902 - J Cell Biochem. 2009 Jul 1;107(4):639-54
– reference: 22355275 - Neoplasia. 2012 Jan;14(1):65-73
– reference: 19237632 - J Clin Oncol. 2009 Apr 1;27(10):1564-71
– reference: 16572175 - Nature. 2006 Mar 30;440(7084):692-6
– reference: 16120859 - N Engl J Med. 2005 Aug 25;353(8):793-802
– reference: 23018462 - J Immunol. 2012 Nov 1;189(9):4258-65
– reference: 15599396 - J Clin Invest. 2004 Dec;114(12):1714-25
– reference: 10485497 - Cancer Res. 1999 Sep 1;59(17):4453-7
– reference: 7585222 - Nat Med. 1995 Sep;1(9):944-9
– reference: 12763924 - Blood. 2003 Sep 15;102(6):2060-7
– reference: 9153295 - J Clin Invest. 1997 May 15;99(10):2509-17
– reference: 9473237 - Blood. 1998 Mar 1;91(5):1706-15
– reference: 8753751 - Urology. 1996 Aug;48(2):317-25
– reference: 23515621 - J Mol Med (Berl). 2013 Apr;91(4):411-29
– reference: 20703299 - Nature. 2010 Aug 12;466(7308):829-34
– reference: 11402070 - J Cell Biol. 2001 Jun 11;153(6):1277-86
– reference: 12154351 - Nat Rev Cancer. 2002 Aug;2(8):584-93
– reference: 2686530 - Anticancer Res. 1989 Sep-Oct;9(5):1291-9
– reference: 20100959 - J Clin Oncol. 2010 Mar 1;28(7):1099-105
– reference: 16862154 - Nat Med. 2006 Aug;12(8):933-8
– reference: 17371949 - Blood. 2007 Jul 1;110(1):133-41
– reference: 16341007 - Nature. 2005 Dec 8;438(7069):820-7
– reference: 1317363 - Int J Cancer. 1992 May 28;51(3):416-24
– reference: 20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23
– reference: 12919697 - Bone. 2003 Jul;33(1):28-37
– reference: 17483337 - Cancer Res. 2007 May 1;67(9):4254-63
– reference: 12602924 - Breast Cancer Res Treat. 2003 Feb;77(3):245-52
– reference: 8944003 - J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7
– reference: 21159629 - Cancer Res. 2010 Dec 15;70(24):10044-50
– reference: 15730850 - Exp Hematol. 2005 Mar;33(3):272-8
– reference: 22805007 - Int J Urol. 2012 Nov;19(11):968-79
– reference: 15816522 - Anticancer Res. 2005 Jan-Feb;25(1A):79-83
– reference: 22820642 - Nat Med. 2012 Aug;18(8):1224-31
– reference: 22836751 - Cancer Res. 2012 Sep 15;72(18):4662-71
– reference: 17942921 - Cancer Res. 2007 Oct 15;67(20):9894-902
– reference: 3280598 - J Clin Invest. 1988 Apr;81(4):1012-9
– reference: 15187021 - Blood. 2004 Oct 15;104(8):2484-91
– reference: 17909051 - Cancer Res. 2007 Oct 1;67(19):9417-24
– reference: 9850077 - Cancer Res. 1998 Dec 1;58(23):5439-46
– reference: 9204896 - Science. 1997 Jul 4;277(5322):55-60
– reference: 15367435 - Blood. 2005 Jan 1;105(1):178-85
– reference: 23482834 - Oncoimmunology. 2013 Jan 1;2(1):e22338
– reference: 20863401 - Mol Cancer. 2010;9:258
– reference: 10344214 - Prostate. 1999 Jun 1;39(4):246-61
– reference: 16462802 - Nat Med. 2006 Feb;12(2):235-9
– reference: 22524673 - J Immunotoxicol. 2012 Jul-Sep;9(3):241-7
– reference: 14695408 - N Engl J Med. 2003 Dec 25;349(26):2483-94
– reference: 15084698 - N Engl J Med. 2004 Apr 15;350(16):1655-64
– reference: 12154349 - Nat Rev Cancer. 2002 Aug;2(8):563-72
– reference: 9815680 - Clin Cancer Res. 1997 Feb;3(2):249-56
– reference: 19915614 - Oncogene. 2010 Feb 11;29(6):811-21
– reference: 17159986 - Nat Med. 2007 Jan;13(1):62-9
– reference: 23810565 - Cancer Cell. 2013 Jul 8;24(1):130-7
– reference: 17132226 - Neoplasia. 2006 Nov;8(11):939-48
– reference: 23728425 - Nat Cell Biol. 2013 Jul;15(7):807-17
– reference: 2673568 - Cancer Metastasis Rev. 1989 Aug;8(2):98-101
– reference: 1283500 - Adv Exp Med Biol. 1992;324:255-68
– reference: 23277196 - Biochim Biophys Acta. 2013 Jul;1834(7):1449-59
– reference: 15011745 - In Vivo. 2004 Jan-Feb;18(1):1-14
– reference: 19597504 - Nat Med. 2009 Aug;15(8):960-6
– reference: 12788977 - Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52
– reference: 11389070 - Cancer Res. 2001 Jun 1;61(11):4418-24
– reference: 15894268 - Cancer Cell. 2005 May;7(5):485-96
– reference: 10096570 - Cancer Res. 1999 Mar 15;59(6):1356-61
– reference: 22635005 - Nat Med. 2012 Jun;18(6):883-91
– reference: 11124582 - Neuroimmunomodulation. 2000;8(3):154-64
– reference: 11923519 - Science. 2002 Mar 29;295(5564):2387-92
– reference: 8120958 - JAMA. 1994 Mar 23-30;271(12):907-13
– reference: 8546226 - Am J Pathol. 1996 Jan;148(1):55-61
– reference: 10700237 - Nat Med. 2000 Mar;6(3):332-6
– reference: 20850578 - Bone. 2011 Jan;48(1):54-65
– reference: 12842083 - Cancer Cell. 2003 Jun;3(6):537-49
– reference: 14524530 - Clin Exp Metastasis. 2003;20(5):413-20
– reference: 19213681 - N Engl J Med. 2009 Feb 12;360(7):679-91
– reference: 20501944 - J Clin Invest. 2010 Jun;120(6):2030-9
– reference: 22648501 - Nature. 2012 May 31;485(7400):S58-9
– reference: 17129361 - Cancer Sci. 2007 Jan;98(1):127-33
– reference: 11854515 - Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8
– reference: 15168730 - Clin Exp Metastasis. 2004;21(2):129-38
– reference: 23680145 - Cancer Cell. 2013 May 13;23(5):573-81
– reference: 22124112 - J Exp Med. 2011 Dec 19;208(13):2641-55
– reference: 21207426 - Int J Cancer. 2011 Nov 15;129(10):2522-6
– reference: 15199115 - J Natl Cancer Inst. 2004 Jun 16;96(12):956-65
– reference: 9142127 - Nat Med. 1997 May;3(5):558-61
– reference: 22266111 - Cancer Res. 2012 Mar 1;72(5):1199-209
– reference: 9182762 - Cell. 1997 May 30;89(5):747-54
– reference: 11120755 - J Clin Invest. 2000 Dec;106(12):1481-8
– reference: 15378518 - Prostate. 2005 Mar 1;62(4):394-9
– reference: 14612570 - Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
– reference: 17312308 - J Natl Cancer Inst. 2007 Feb 21;99(4):309-21
– reference: 22952424 - Neoplasia. 2012 Aug;14(8):709-18
– reference: 11242036 - Nature. 2001 Mar 1;410(6824):50-6
– reference: 3745206 - J Biol Chem. 1986 Sep 25;261(27):12665-74
– reference: 19608765 - Genes Dev. 2009 Aug 15;23(16):1882-94
– reference: 15093540 - Cancer Cell. 2004 Apr;5(4):329-39
– reference: 19475568 - J Cell Physiol. 2009 Oct;221(1):98-108
– reference: 16523199 - Br J Cancer. 2006 Mar 27;94(6):842-53
– reference: 18820689 - Nat Cell Biol. 2008 Nov;10(11):1349-55
– reference: 1713592 - J Cell Biol. 1991 Aug;114(3):557-65
SSID ssj0004402
Score 2.4553785
SecondaryResourceType review_article
Snippet Bone metastasis is a frequent occurrence in late stage solid tumors, including breast cancers, prostate or lung. However, the causes for this proclivity have...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 222
SubjectTerms Animals
Biological and medical sciences
Bone Neoplasms - metabolism
Bone Neoplasms - secondary
Bone Remodeling
Diseases of the osteoarticular system
Humans
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - metabolism
Neoplasms - pathology
Stromal Cells - metabolism
Tumors
Tumors of striated muscle and skeleton
Title Targeting tumor–stromal interactions in bone metastasis
URI https://www.ncbi.nlm.nih.gov/pubmed/24140083
https://www.proquest.com/docview/1490703476
https://www.proquest.com/docview/1524417381
https://pubmed.ncbi.nlm.nih.gov/PMC3947254
Volume 141
WOSCitedRecordID wos000329950900009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1879-016X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0004402
  issn: 0163-7258
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZpu4fBGLsvuwQPRp_qEEuyZT2WkrFryUM2spcFyZZoSuOY2Cndv9_RJbbTldEN9mIS24osf0dHn5TvHCH0VmpCqY6iUHElQpqno1BQLUMhR1wQBpzdpl389pmdnqazGZ_0ej-2sTCXF6wo0qsrXv5XqOEcgG1CZ_8C7uZH4QR8BtDhCLDD8XbAW223jYLaLFfrsKrXq6VNrWGCjbNGOy5XwC-XqhbAD6tF1WWpkzaftRPUdKK07CqtCzPsrCKMnfprdT3855Nfjv6-kD7Ft19hiOhWlNwuOiYkZNilWB8q5yhTZnRWdhfC1pPSqGMyuOsXXfCxH2Kxy33xm_d2Cwnnw9K00rbMaO_I0MnvukXglZdLCyAwEGp4ZDueNSrDyZcTwik8ON1DB5jFHLzewfGH8exjGzlLrSq1aaHXejkF4M2PYdJH-zp3uMy9UlTQrbTbD-WmCct13W2HyEwfoPt-BhIcO8t5iHqqeIQOPeQ_j4JpB-uj4DDoGsNjxBrzCnbMK-iaF3wJjHkFrXk9QV_fjacn70O_-UaYxZTXYUaAO6YEyIvAGkusNNWZSR6U0zhjIy4VFmKkNBGRFMDCCeWRSkSsmVYZzhPyFO0XUNNzFCSaSh1zCd0e4CB5CuNILlOc65SIVER9xLavcZ75zPRmg5SL-VaCeD5vsZgbLMwVwKKPoqZk6bKz3KLMYAeppiC01k53-ujNFro5-FrzB5oo1GpTwTSZmxGSsuQP98TY7OoHRLiPnjm42xq83UCDdwyhucHket-9UizObM53b8gv_rnkS3S37duv0H693qjX6E52WS-q9QDtsVk68L3jF9yx0pg
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+tumor-stromal+interactions+in+bone+metastasis&rft.jtitle=Pharmacology+%26+therapeutics+%28Oxford%29&rft.au=Esposito%2C+Mark&rft.au=Kang%2C+Yibin&rft.date=2014-02-01&rft.issn=0163-7258&rft.eissn=1879-016X&rft.volume=141&rft.issue=2&rft.spage=222&rft.epage=233&rft_id=info:doi/10.1016%2Fj.pharmthera.2013.10.006&rft_id=info%3Apmid%2F24140083&rft.externalDocID=PMC3947254
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-7258&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-7258&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-7258&client=summon